Michael Metzger

Metzger brings to Mersana nearly 20 years of experience within the life sciences and pharmaceuticals industries.

At Forest Laboratories, he led the mergers and acquisitions function, where he completed deals with Cerexa and Novexel, together forming the cornerstone of Forest's hospital antibiotic franchise, and most recently led the successful acquisition of Clinical Data, Inc.

He also led the US co-development and co-promotion deal with Ironwood Pharmaceuticals for Linaclotide. Prior to Forest, Mr. Metzger was Vice President of Corporate Development at Onconova Therapeutics, where he was responsible for the company's business development and financial initiatives.

He also served as Managing Director at MESA Partners, a venture capital firm focused on healthcare and IT companies. He serves as a member of the Board of Directors and Chairman of the Finance Committee of Response Genetics, Inc., (NASDAQ: RGDX) a company focused on the development and commercialization of molecular diagnostic tests for cancer.

Mr. Metzger earned his B.A. from George Washington University and an M.B.A. in Finance from New York University's Stern School of Business.

Michael Metzger is the Member Board Of DirectorsMember at Tarveda Therapeutics, based in United States, North America. With a background in Biotechnology, Michael Metzger has a rich history of leadership and innovation. Michael Metzger studied MBA unknown @ NYU Stern School of Business. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.